Straits Times Index
3,258.90 +1.72 (+0.05%) Nikkei
28,041.48 +258.55 (+0.93%) Hang Seng
20,400.11 +90.98 (+0.45%) FTSE 100
7,631.74 +11.31 (+0.15%) Bitcoin USD
28,440.63 +14.67 (+0.05%) CMC Crypto 200
621.79 +7.58 (+1.23%)
ABBV Aug 2023 135.000 put
| Previous close | 2.2000 |
| Open | 2.2000 |
| Bid | 1.8700 |
| Ask | 1.9800 |
| Strike | 135.00 |
| Expiry date | 2023-08-18 |
| Day's range | 2.2000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.46k |
- Motley Fool
Could This Drug News Lift AbbVie's Stock?
Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.
- Motley Fool
The Top Healthcare Stocks to Buy With $100
A common misconception is that you need a lot of money to invest in the stock market. Let's look at three healthcare stocks that can be purchased for $100 and have good prospects to grow over time. The stock hasn't been off to a great start this year, dipping 18%, but the odds look pretty good for the company in the near future.
- Motley Fool
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). Let's examine the data from the clinical trial and the U.S. UC market to resolve this question. Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes damage to the gastrointestinal (GI) tract.
